此外，AstralBio将有资格获得总计高达2800万美元的开发和商业化里程碑付款。如果iBio对已授权产品进行再授权，AstralBio将从收益中获得2%-7%的再授权费用。iBio (IBIO.US) announced on Thursday that it has obtained the license for long-acting myostatin-inhibitory antibodies from AstralBio, thereby expanding its cardiovascular metabolism and obesity treatment development projects.
Zhitong Finance APP learned that iBio (IBIO.US) announced on Thursday that it has obtained a license for AstralBio's long-acting anti-myostatin antibody, thereby expanding its cardiac metabolism and obesity treatment development projects. The antibody is currently named iBio-600, identified by AstralBio using iBio's proprietary technology, designed for subcutaneous administration with the potential for an extended half-life.
According to the agreement, AstralBio will receive a $0.75 million upfront payment, which iBio has paid by issuing common stock to AstralBio. As of the time of writing, iBio is up 2.04% in Pre-Market Trading.
In addition, AstralBio will be eligible to receive a total of up to $28 million in development and commercialization milestone payments. If iBio sublicenses the authorized products, AstralBio will receive a 2%-7% royalty from the revenues.
At the same time, iBio has launched a dual-specific antibody program targeting myostatin/activin A, utilizing its proprietary drug discovery platform and iBio-600 technology to treat obesity and cardiac metabolic disorders.
